Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of low-risk post-molar gestational trophoblastic tumor, defined as 1 of the following:
• * Increasing human chorionic gonadotropin (hCG) levels on ≥ 3 consecutive measurements taken over ≥ a 2-week period
• * Less than 10% decrease of hCG levels on 4 measurements taken over ≥ a 3-week period
• Persistent or recurrent disease
• Histologically confirmed complete or partial mole on initial evacuation
• * Prior pregnancy ≤ 12 months ago
• No histologically confirmed choriocarcinoma or placental site trophoblastic tumor on initial evacuation
• Failed only 1 prior dactinomycin or methotrexate therapy (with or without leucovorin calcium)
• WHO score 2-6
• No evidence of metastatic disease, except to the lung or vagina, on physical exam, chemistry, chest X-ray, and ultrasound
• * No liver, spleen, brain, kidney, or gastrointestinal tract metastases
• * No more than 8 metastatic lesions
• PATIENT CHARACTERISTICS:
• Age
• Any age
• Performance status
• GOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Granulocyte count ≥ 1,500/mm\^3
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• SGOT ≤ 3 times ULN
• Alkaline phosphatase ≤ 3 times ULN
• Renal
• Creatinine ≤ 1.5 mg/dL
• Creatinine clearance ≥ 45 mL/min
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 3 months after study participation
• No significant infection
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent prophylactic filgrastim (G-CSF) unless for recurrent neutropenic complications
• No concurrent prophylactic thrombopoietic agents unless for recurrent grade 4 thrombocytopenia
• Chemotherapy
• See Disease Characteristics
• At least 7 days since prior dactinomycin or methotrexate (with or without leucovorin calcium) and recovered
• No prior pemetrexed disodium
• No other prior chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• At least 14 days since prior radiotherapy and recovered
• No prior radiotherapy to ≥ 25% of the bone marrow
• Surgery
• Recovered from prior surgery
• Other
• No nonsteroidal anti-inflammatory drugs or salicylates for 2 days (or 5 days for drugs with a long half-life) before, during, and for 2 days after pemetrexed disodium administration
• * Concurrent low-dose aspirin (≤ 325 mg/day) allowed